Global Quadrivalent Flu Vaccine Market Overview:
The quadrivalent flu vaccine is designed to protect against four different flu viruses such as two influenzas A viruses and two influenza B viruses. Different vaccines are approved for different age groups. There is a quadrivalent flu shot that can be given to children as young as sixth months of age. Other quadrivalent flu shots are approved for people three years and older.
Growth Drivers
- Growing Health Awareness across the Globe
- The Increasing Flu Prevalence Worldwide
Roadblocks
- High Manufacturing Cost Involved in Adult Vaccines
- Stringent Regulatory Guidelines
Opportunities
- Rising Demand from Emerging Countries
- World Health Organization (WHO) Favorable Initiatives
Challenges
- High Cost Involved in Research and Development
Competitive Landscape:
Some of the key players profiled in the report are AstraZeneca (United Kingdom), CSL Limited (Australia), GlaxoSmithKline (United Kingdom), Sanofi (France), Altimmune (United States), BionVax (Israel), FluGen (United States), FOLIA BIOTECH Inc. (Canada), Novavax (United States) and SK Chemicals (South Korea). Additionally, following companies can also be profiled that are part of our coverage like Shijiazhuang Yiling Pharmaceutical (China), Vaccitech (United Kingdom) and Vaxine Pty (Australia). Analyst at AMA Research see United States and United Kingdom Players to retain maximum share of Global Quadrivalent Flu Vaccine market by 2026. Considering Market by Age Group, the sub-segment i.e. Adults will boost the Quadrivalent Flu Vaccine market.
On 15 July 2019, GSK announced that it will begin shipping its quadrivalent influenza vaccines to United States healthcare providers and pharmacies for the 2019-20 flu season, immediately following licensing and lot-release approval from the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research.
What Can be Explored with the Quadrivalent Flu Vaccine Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Quadrivalent Flu Vaccine Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Quadrivalent Flu Vaccine
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Quadrivalent Flu Vaccine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Quadrivalent Flu Vaccine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Quadrivalent Flu Vaccine Manufacturers, Quadrivalent Flu Vaccine Traders/Distributors, Quadrivalent Flu Vaccine Importer/Exporter, Regulatory & Government Bodies, Research & Consulting Firms, End Users and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.